Metrics
Publication
15
Biography
After completing my Ph.D. on
nicotine addiction under Ian P. Stolerman at the Institute of Psychiatry,
King’s College London, I embarked on a career dedicated to advancing the
science of nicotine dependence. My early postdoctoral work at the Max-Planck
Institute for Psychiatry in Munich produced influential publications, followed
by a prolific period at the Addiction Research Center in Baltimore, where I
collaborated with Steve Goldberg on nicotine self-administration studies. In
recognition of this work, I received the SRNT Outstanding Young Investigator
Paper Session Award in 1996. Throughout my career, my research has focused on
the neurobiological determinants of nicotine dependence, with a particular
emphasis on developing translational models to evaluate the clinical efficacy
of smoking cessation agents while working as a senior lecturer at Newcastle
University, UK. This programme of work has contributed to a deeper
understanding of addiction mechanisms and informed strategies for therapeutic
intervention, reinforcing my commitment to bridging laboratory science with
clinical application.
Education
1988 - 1992
1988 - 1992Doctorate
University of London-Kings College London, Institute of Psychiatry, Behavioural Pharmacology, England
1985 - 1988
1985 - 1988Postgraduate
University of Sunderland, Life Sciences, Pharmacology, England
Research Areas
Research Areas Based on Academic Activities
Avesis Research Areas
WoS Research Areas
Scopus Research Areas
Academic Positions
2023 - Present
2023 - PresentProfessor
University of Hertfordshire, Life SSciences, Pharmacology
2003 - 2021
2003 - 2021Associate Professor
Newcastle University, Medical Sciences, Behavioural Neuroscience
1996 - 2003
1996 - 2003Associate Professor
University of London-Kings College London, Institute of Psychiatry, Behavioural Pharmacology
Articles
2025
20251. Selective Effects of Acutely Administered N-Acetyl-Cysteine in Rodent Models of Nicotine-Conditioned Behaviours
Stoddart K., Davies M., Oughton J., Malcolm E., AlSharari S. D., Shoaib M.
Addiction Biology , vol.30, no.9, 2025 (SCI-Expanded, Scopus)
2021
20212. Pentylenetetrazol-like stimulus is not produced following naloxone-precipitated mitragynine withdrawal in rats.
Johari I. S., Harun N., Sofian Z. M., Shoaib M.
Psychopharmacology , vol.238, no.11, pp.3183-3191, 2021 (SCI-Expanded, Scopus)
2020
20203. Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats.
Harun N., Johari I. S., Mansor S. M., Shoaib M.
Psychopharmacology , vol.237, no.3, pp.855-867, 2020 (SCI-Expanded, Scopus)
2015
20154. Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats.
Malcolm E., Carroll F. I., Blough B., Damaj M. I., Shoaib M.
Psychopharmacology , vol.232, no.15, pp.2763-71, 2015 (SCI-Expanded, Scopus)
2015
20155. Discriminative stimulus properties of mitragynine (kratom) in rats.
Harun N., Hassan Z., Navaratnam V., Mansor S. M., Shoaib M.
Psychopharmacology , vol.232, no.13, pp.2227-38, 2015 (SCI-Expanded, Scopus)
2015
20156. Concurrent access to nicotine and sucrose in rats.
Panlilio L. V., Hogarth L., Shoaib M.
Psychopharmacology , vol.232, no.8, pp.1451-60, 2015 (SCI-Expanded, Scopus)
2012
20127. Translating the smoking cessation properties of the antidepressant nortriptyline using reinforcing, discriminative and aversive stimulus effects of nicotine in rats.
Wing V. C., Shoaib M.
Psychopharmacology , vol.219, no.3, pp.847-57, 2012 (SCI-Expanded, Scopus)
2011
20118. Neuroanatomical targets of reboxetine and bupropion as revealed by pharmacological magnetic resonance imaging.
Sekar S., Van Audekerke J., Vanhoutte G., Lowe A. S., Blamire A. M., Van der Linden A., et al.
Psychopharmacology , vol.217, no.4, pp.549-57, 2011 (SCI-Expanded, Scopus)
2011
20119. Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement.
Hahn B., Shoaib M., Stolerman I. P.
Psychopharmacology , vol.217, no.1, pp.75-82, 2011 (SCI-Expanded, Scopus)
2011
201110. Neuroadaptive responses to citalopram in rats using pharmacological magnetic resonance imaging.
Sekar S., Verhoye M., Van Audekerke J., Vanhoutte G., Lowe A. S., Blamire A. M., et al.
Psychopharmacology , vol.213, no.2-3, pp.521-31, 2011 (SCI-Expanded, Scopus)
2010
201011. Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats.
Ismayilova N., Shoaib M.
Psychopharmacology , vol.210, no.2, pp.211-20, 2010 (SCI-Expanded, Scopus)
2008
200812. Contextual stimuli modulate extinction and reinstatement in rodents self-administering intravenous nicotine.
Wing V. C., Shoaib M.
Psychopharmacology , vol.200, no.3, pp.357-65, 2008 (SCI-Expanded, Scopus)
2007
200713. Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Wing V. C., Shoaib M.
Psychopharmacology , vol.195, no.3, pp.303-13, 2007 (SCI-Expanded, Scopus)
2006
200614. Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence.
Shoaib M.
Psychopharmacology , vol.188, no.2, pp.252-7, 2006 (SCI-Expanded, Scopus)
1999
199915. Plasma nicotine and cotinine levels following intravenous nicotine self-administration in rats.
Shoaib M., Stolerman I. P.
Psychopharmacology , vol.143, no.3, pp.318-21, 1999 (SCI-Expanded, Scopus)
Memberships and Roles in Scientific Organizations
2026 - Present
2026 - Present